| Literature DB >> 25202711 |
Paola Lucia Minciullo1, Michele Navarra2, Gioacchino Calapai3, Sebastiano Gangemi4.
Abstract
Benzene represents an ubiquitous pollutant both in the workplace and in the general environment. Health risk and stress posed by benzene have long been a concern because of the carcinogenic effects of the compound which was classified as a Group 1 carcinogen to humans and animals. There is a close correlation between leukemia, especially acute myeloid leukemia, and benzene exposure. In addition, exposure to benzene can cause harmful effects on immunological, neurological, and reproductive systems. Benzene can directly damage hematopoietic progenitor cells, which in turn could lead to apoptosis or may decrease responsiveness to cytokines and cellular adhesion molecules. Alternatively, benzene toxicity to stromal cells or mature blood cells could disrupt the regulation of hematopoiesis, including hematopoietic commitment, maturation, or mobilization, through the network of cytokines, chemokines, and adhesion molecules. Today there is mounting evidence that benzene may alter the gene expression, production, or processing of several cytokines in vitro and in vivo. The purpose of this review was to systematically analyze the published cases of cytokine effects on human benzene exposure, particularly hematotoxicity, and atopy, and on lungs.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25202711 PMCID: PMC4151491 DOI: 10.1155/2014/937987
Source DB: PubMed Journal: J Immunol Res ISSN: 2314-7156 Impact factor: 4.818
Summary of considered studies on hematotoxicity induced by benzene and/or its metabolites.
| Cytokine involved | Substance(s) | Effect(s) | Reference |
|---|---|---|---|
|
TNF- | Benzene | Similar peripheral levels in exposed subjects and controls | Rothman et al., 1996 [ |
| HQ | Dose-dependent inhibition of TNF- | Kerzic et al., 2003 [ | |
| Synergistic action of hydroquinone and TNF- | Kerzic et al., 2003 [ | ||
| Benzene | −238 (G→A) polymorphism is associated with the development of persistent bone marrow dysplasia developing in patients previously exposed to benzene | Lv et al., 2007 [ | |
| HQ, benzenetriol, BQ, and catechol | Dose-dependent increase in TNF- | Gillis et al., 2007 [ | |
| BTX | Dose-dependent reduction in TNF production by PBMC | Haro-García et al., 2012 [ | |
|
| |||
| IL-1 | HQ | Prevention of the proteolytic conversion of pre-IL-l |
Renz and Kalf, 1991 [ |
| HQ | Dose-dependent reduction of IL-1 |
Carbonnelle et al., 1995 [ | |
| HQ | Inhibition of pre-interleukin-l | Niculescu et al., 1995 [ | |
| HQ, catechol | Suppression of IL-1 | Gillis et al., 2007 [ | |
| Benzene | −889 (C > T) polymorphism is associated with the decrease of granulocyte count | Lan et al., 2005 [ | |
|
| |||
| IL-2 | BQ | Decrease in IL-2 production by activated PBMC | Gillis et al., 2007 [ |
|
| |||
| IL-3 | Benzene | Nondetectable peripheral levels | Rothman et al., 1996 [ |
|
| |||
| IL-4 | Benzene | −1098 (T > G) polymorphism is associated with decreased granulocyte and total lymphocytes counts | Lan et al., 2005 [ |
|
| |||
| IL-6 | Benzene | Similar peripheral levels in exposed subjects and controls | Rothman et al., 1996 [ |
| Benzenetriol, BQ, and catechol | Increased IL-6 production by activated PBMC | Gillis et al., 2007 [ | |
|
| |||
| IL-10 | Benzene | No statistically significant difference in peripheral levels of exposed subjects and controls | Spatari et al., 2013 [ |
| BMX | No statistically significant dose-dependent reduction in IL-10 production by PBMC | Haro-García et al., 2012 [ | |
| HQ, catechol | Strong inhibition of IL-10 production by activated PBMC | Gillis et al., 2007 [ | |
| Benzene | −819 (T > C) polymorphism is associated with the decrease of granulocyte count | Lan et al., 2005 [ | |
|
| |||
| IL-12 | BMX | No statistically significant dose-dependent reduction in IL-10 production by PBMC | Haro-García et al., 2012 [ |
| Benzene | −8685 (G > A) polymorphism is associated with decreased granulocytes, total lymphocyte count, and CD4+ and CD8+ T-cell subsets. | Lan et al., 2005 [ | |
|
| |||
| IFN- | HQ | Increased IFN- | Gillis et al., 2007 [ |
|
| |||
| VCAM1 | Benzene | −1591 (T > C) polymorphism is associated with decreased B cells, natural killer cells, CD4+ T cells, and monocytes and colony-forming unit granulocyte-erythroid-macrophage-megakaryocyte progenitor cells | Lan et al., 2005 [ |
|
| |||
| PF4 | Benzene | Downregulation of the expression | Vermeulen et al., 2005 [ |
|
| |||
| CTAP-III | Benzene | Downregulation of the expression | Vermeulen et al., 2005 [ |
|
| |||
| CXCL12 | BQ | Upregulation of gene expression | Zolghadr et al., 2012 [ |
|
| |||
| IL-8 | HQ, catechol | Increased IL-8 production by PBMC |
Gillis et al., 2007 [ |
| Benzenetriol, BQ | Increased IL-8 production by PBMC | ||
|
| |||
| Eotaxin, MIP1- | HQ, benzenetriol, BQ, and catechol | Increased chemokines production by PBMC | Gillis et al., 2007 [ |
|
| |||
| MCP-1 | HQ, benzenetriol, and BQ | Increased MCP-1 production by PBMC | Gillis et al., 2007 [ |
| HQ, catechol | Decreased IL-8 production by activated PBMC | Gillis et al., 2007 [ | |
HQ: hydroquinone; BQ: benzoquinone; BTX: benzene-toluene-xylene mixture; PBMC: peripheral blood mononuclear cells; PF4: platelet factor 4; CTAP-III: connective tissue activating peptide; CXCL: CXC chemokine ligand.
Summary of considered studies on atopy induced by benzene and/or its metabolites.
| Population | Exposure substance(s) | Effect(s) | Reference |
|---|---|---|---|
| Nonatopic and atopic women | Vehicular traffic and low air pollution | No difference in urinary | Boscolo et al., 2000 [ |
| Nonatopic and atopic women | Vehicular traffic and low air pollution | Stimulation of NK activity | Boscolo et al., 2000 [ |
| 3-year-old children | Chlorobenzene | Contribution to the risk of allergic sensitization to the food allergens milk and egg white | Lehmann et al., 2001 [ |
| 3-year-old children | Benzene, ethylbenzene, and chlorobenzene | Increased IL-4 producing CD3+ T cells | Lehmann et al., 2001 [ |
| Healthy subjects | HQ, benzenetriol, BQ, and catechol | Increased secretion of IL-4 | Gillis et al., 2007 [ |
| Healthy subjects | HQ, catechol | Increased secretion of IL-5 | Gillis et al., 2007 [ |
HQ: hydroquinone; BQ: benzoquinone.